semiautomatic gradient-based contouring algorithm (MIMVista corp)
90
Structured Review
MIMVista corp
semiautomatic gradient-based contouring algorithm
Semiautomatic Gradient Based Contouring Algorithm, supplied by MIMVista corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gradient-based+algorithms/semiautomatic+gradient+based+contouring+algorithm/pm39862898-65-4-5
Average 90 stars, based on 1 article reviews
Semiautomatic Gradient Based Contouring Algorithm, supplied by MIMVista corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gradient-based+algorithms/semiautomatic+gradient+based+contouring+algorithm/pm39862898-65-4-5
Average 90 stars, based on 1 article reviews
semiautomatic gradient-based contouring algorithm - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Daily Step Counts: A New Prognostic Factor in Locally Advanced Non-Small Cell Lung Cancer? Article Snippet: Introduction Here we explore the prognostic value of baseline step count data captured using wearable devices for patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC).. Methods Locally advanced NSCLC patients wore a commercial fitness tracker during a course of definitive, concurrent chemoradiotherapy as part of a clinical trial.. Baseline step count average was defined as the average daily step total from study enrollment until completion of the first week of radiotherapy. Article Title: Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT). Article Snippet: Background Standard radiotherapy (RT) for locally advanced NSCLC (LA-NSCLC) employs a uniform dose of approximately 60 Gy.. Recent trials demonstrated that radiotherapy dose escalation may not improve outcomes and may cause added toxicity.. XXX previously performed a single-arm trial testing a personalized, risk-adapted, and deintensified RT strategy. Article Title: Cardiac Irradiation Predicts Activity Decline in Patients Receiving Concurrent Chemoradiation for Locally Advanced Lung Cancer. Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Article Title: Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory Analysis. Article Snippet: As a measure of Article Title: Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer Article Snippet: As a measure of disease burden and gross tumor volume, pre-treatment total metabolic tumor volume (MTV) was calculated from each patient’s staging PET/CT using a semiautomatic gradient-based contouring |